Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve
- Development stage
- Phase 2
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium breve* is a gram-positive, anaerobic, branched rod-shaped probiotic bacterium that is a prominent member of the human gut microbiota, particularly in breast-fed infants. As a live biotherapeutic product, it is utilized for its ability to modulate the intestinal environment, enhance gut barrier function, and regulate immune responses. *B. breve* exerts its effects through competitive exclusion of pathogens, production of short-chain fatty acids (SCFAs) like acetate, and interaction with the host immune system via Toll-like receptors. Clinical research has investigated its efficacy in treating various conditions, including irritable bowel syndrome (IBS), ulcerative colitis, acute diarrhea, and pediatric asthma. It is also explored for its metabolic benefits in obesity and its potential to reduce allergic symptoms such as atopic dermatitis.
- Brand names
- Brevicillin
- Other names
- 短双歧杆菌B. breveBifidobacterium brevis
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Bifidobacterium breve.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve.